- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 29.09. | Regeneron's Evkeeza gains FDA approval for young HoFH patients | ||
| 26.09. | AstraZeneca launches DTC platform amid US pricing pressures | ||
| 26.09. | Drugmakers point to US expansion plans amid Trump's 100% drug tariff | ||
| 26.09. | FDA approves Lilly's Inluriyo to treat advanced breast cancer | ||
| 26.09. | European PE company prioritising CGT and other novel modality investments | ||
| 26.09. | Harmony's cannabidiol drug flops in pivotal Fragile X Syndrome trial | ||
| 26.09. | Synaffix and Qurient enter licensing deal for dual-payload ADC | ||
| 25.09. | MSD pays up to nearly $600m for Evaxion's mystery vaccine candidate | ||
| 25.09. | BMS expands DTC offering with Sotyktu addition | ||
| 25.09. | FDA delays approval decision for Sanofi's MS treatment tolebrutinib | ||
| 25.09. | Biogen's high-dose Spinraza turned down by FDA due to CMC troubles | ||
| 25.09. | Basilea in line for $159m of US federal funding for UTI antibiotic pill | ||
| 25.09. | Roche bids to broaden MS pipeline and strengthen Ocrevus influence | ||
| 25.09. | Sanofi announces $625m to venture capital arm | ||
| 24.09. | Eli Lilly to build $6.5bn orforglipron production site in Texas | ||
| 24.09. | Imunon's Phase III-stage IL-12 gene therapy alters tumour microenvironment in ovarian cancer | ||
| 24.09. | FDA to priority-review Daiichi Sankyo and AZ's Enhertu sBLA | ||
| 24.09. | TegMine and Boehringer Ingelheim partner on cancer therapeutics | ||
| 23.09. | FDA actions Tylenol label change after Trump's autism claim | ||
| 23.09. | Bill Gates pledges $912m to combat infectious diseases amid US funding cuts | ||
| 23.09. | Innovative mental health treatment tech struggles for traction as pharma dominates | ||
| 23.09. | EC approves Servier's Voranigo to treat IDH-mutant glioma | ||
| 23.09. | Merck KGaA and Siemens extend digital transformation partnership in life sciences | ||
| 22.09. | Pfizer buys monthly GLP-1RA developer Metsera for $4.9bn | ||
| 22.09. | MSD wins SC Keytruda approval, but analysts sceptical on impact |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .